Metal Chelation Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Metal chelation therapy aims to restore metal homeostasis in the brain by removing excess transition metals that contribute to oxidative stress, protein aggregation, and neuronal death. Iron and copper accumulation is a hallmark of many neurodegenerative diseases, making metal homeostasis a compelling therapeutic target [1].
Iron accumulation occurs with aging and is accelerated in:
| Property | Value |
|---|---|
| Target | Iron (Fe³⁺) |
| Structure | Hydroxamate siderophore |
| CNS Penetration | Limited |
| Route | Subcutaneous |
| Clinical Use | FDA approved for iron overload |
Evidence in Neurodegeneration:
| Property | Value |
|---|---|
| Target | Iron (Fe³⁺) |
| Structure | Bidentate hydroxyphenylisoxazole |
| CNS Penetration | Moderate |
| Route | Oral |
| Clinical Use | FDA approved for iron overload |
Clinical Trials:
| Property | Value |
|---|---|
| Target | Copper, Zinc |
| Structure | 8-hydroxyquinoline |
| CNS Penetration | Moderate |
| Route | Oral |
| Status | Discontinued |
Clinical Trials:
| Property | Value |
|---|---|
| Target | Copper, Zinc |
| Structure | 8-hydroxyquinoline (synthetic) |
| CNS Penetration | High |
| Route | Oral |
| Status | Phase 2 |
Clinical Trials:
| Agent | Target | Stage | Notes |
|---|---|---|---|
| VAR10403 | Iron | Preclinical | Novel small molecule |
| M30 | Iron, copper | Preclinical | Multifunctional |
| DP-b99 | Iron, copper | Phase 2 | Lipid-soluble |
| Trientine | Copper | Approved (Wilson's) | Being explored in AD |
Rationale:
Clinical Evidence:
Rationale:
Clinical Evidence:
Rationale:
Clinical Evidence:
| Combination | Rationale | Status |
|---|---|---|
| Deferoxamine + CoQ10 | Iron removal + mitochondrial support | Preclinical |
| PBT2 + Memantine | Metal homeostasis + NMDA modulation | Planned |
Careful balance needed - some iron necessary for normal function.
| Biomarker | Use | Method |
|---|---|---|
| Serum ferritin | Iron status | ELISA |
| CSF ferritin | Brain iron | Lumipulse |
| MRI (R2*) | Brain iron quantification | MRI |
| DMT1 expression | Iron transport | qPCR |
The study of Metal Chelation Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Ward RJ, Zucca FA, Bellei P, et al. Brain iron metabolism: from molecular mechanisms to clinical significance. Antioxid Redox Signal. 2014;20(8):1324-1343. DOI:10.1089/ars.2013.2329
[2] Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004;5(11):863-873.
[3] Crapper McLachlan DR, Dalton AJ, Kruck TP, et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet. 1991;337(8753):1304-1308.
[4] Devos D, Moreau C, Devedjian JC, et al. Targeting chelatable iron as a disease-modifying therapy in Parkinson's disease: the FAIRPARKII study. Lancet. 2014;383(9936):221-228.
[5] Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot Phase 2 clinical trial. Arch Neurol. 2003;60(12):1685-1691.
[6] Lannfelt L, Blennow K, Zetterberg H, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a Phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2008;7(9):779-786.
[7] Ayton S, Lei P, Bush AI. Biometals and their therapeutic implications in Alzheimer's disease. Neurobiol Aging. 2015;36(2):567-579.
[8] Martin-Bastida A, Lao-Kaim NP, Loane C, et al. Relationship between nigral iron and disease progression in Parkinson's disease: An MRI study. Mov Disord. 2020;35(5):824-834.